Opinion

Video

Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

Experts discuss which patient populations stand to benefit the most from recently approved bispecific therapies, identifying gaps or opportunities for further patient benefit, as well as the data gaps that exist in understanding the optimal use of bispecific antibodies across various cancer types.

Video content above is prompted by the following:

  • What patient populations stand to benefit the most from recently approved bispecific therapies?
  • Where are gaps or opportunities for patient populations to further benefit from bispecifics?
  • What data gaps exist in understanding the optimal use of bispecific antibodies across various cancer types?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Dr Sundar Jagannath
4 experts in this video
4 experts in this video
Screenshot of a webinar panel discussion with Viet Le, PA-C; Nathan Wong, PhD, MPH; Alison Bailey, MD; and Martha Gulati, MD, MS
World Hepatitis Day graphic | Image Credit: uazzal - stock.adobe.com
2 experts in this video
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo